Catalysts · REGN · CIK 872589 · page 3 of 3

REGN catalysts and FDA events, page 3.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on REGN PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
March 8, 2024Praluent (alirocumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
January 25, 2024Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
January 12, 2024Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
August 18, 2023Veopoz (pozelimab-bbfg)REGNFDA approval—ApprovedFDA Novel Drug Approvals
August 18, 2023PAVBLU® (aflibercept)REGNFDA approval—ApprovedopenFDA Drugs@FDA
Aug 2023Month disclosedEylea®REGNFDA approval—ApprovedSEC 8-K Exhibit 99.1
June 27, 2023PAVBLU® (aflibercept)REGNComplete Response Letter—CRL issuedFDA Complete Response Letters
April 28, 2023Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
March 21, 2023Evkeeza (evinacumab-dgnb)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
February 8, 2023PAVBLU® (aflibercept)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
November 8, 2022Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
September 28, 2022Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
June 7, 2022Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
May 20, 2022Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
October 20, 2021Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
June 14, 2021Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
April 1, 2021Praluent (alirocumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
February 22, 2021Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
February 11, 2021Evkeeza (evinacumab-dgnb)REGNFDA approval—ApprovedopenFDA Drugs@FDA
February 9, 2021Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
October 14, 2020Inmazeb (atoltivimab; maftivimab; odesivimab)REGNFDA approval—ApprovedopenFDA Drugs@FDA
June 25, 2020Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
June 18, 2020Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
May 26, 2020Dupixent (dupilumab)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
September 28, 2018Libtayo (cemiplimab-rwlc)REGNFDA approval—ApprovedopenFDA Drugs@FDA
March 28, 2017Dupixent (dupilumab)REGNFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from REGN’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.